Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancer
US8481001B2 · kind B2 · utility
4Cited by
2References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 8, 2008 |
| Grant date | Jul 9, 2013 |
| Priority date | — |
| Expiry date | Oct 1, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides methods of treating cancer by administering a compound of Formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with other cancer treatments.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.